Omega Therapeutics
General Information | |
Business: | At Omega Therapeutics, our goal is to pioneer a new class of DNA-sequence-targeting, mRNA-encoded therapeutics to fundamentally transform human medicine in the service of patients. Our pioneering OMEGA Epigenomic Programming platform is designed to coopt nature’s universal operating system by harnessing the power of epigenetics, the mechanism for gene control and cell differentiation. We have deciphered the three-dimensional architecture of the human genome and its accompanying regulators, which are organized into distinct and evolutionarily conserved structures called Insulated Genomic Domains, or IGDs. IGDs are the fundamental structural and functional units of gene control and cell differentiation and act as the “control room” of biology. |
Industry: | BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) |
Employees: | 65 |
Founded: | 2016 |
Contact Information | |
Address | 20 Acorn Park Drive, Cambridge, MA 02140. US |
Phone Number | 617-949-4360. |
Web Address | http://www.omegatherapeutics.com |
View Prospectus: | Omega Therapeutics |
Financial Information | |
Market Cap | $794.3mil |
Revenues | $0 mil (last 12 months) |
Net Income | $-37.5 mil (last 12 months) |
IPO Profile | |
Symbol | OMGA |
Exchange | NASDAQ |
Shares (millions): | 7.4 |
Price range | $17.00 - $17.00 |
Est. $ Volume | $125.8 mil |
Manager / Joint Managers | Goldman Sachs/ Jefferies/ Piper Sandler |
CO-Managers | Wedbush Securities |
Expected To Trade: | 7/30/2021 |
Status: | Priced |
Quiet Period Expiration Date: | Available only to Subscribers |
Lock-Up Period Expiration Date: | Available only to Subscribers |
SCOOP Rating | Available only to Subscribers |
Rating Change | Available only to Subscribers |